初治原发性进展型多发性硬化患者中的抗CD20治疗:一项多中心真实世界研究
这项回顾性研究基于法国多发性硬化登记数据库,纳入2016至2021年间基线扩展残疾状态量表评分≤6.5的原发性进展型多发性硬化患者,比较接受抗CD20治疗者与未治疗者的结局。经逆概率治疗加权后,两组至首次确认残疾进展时间无统计学显著差异(HR 1.13,95%CI 0.93-1.36,p=0.2113),至首次复发时间亦无显著差异,MRI活动度两组无显著差异。
要点
- 抗CD20治疗组与未治疗组至首次确认残疾进展时间无统计学显著差异(HR 1.13,95%CI 0.93-1.36)。
- 治疗组严重感染发生率高于未治疗组(每100人年6.67 vs 2.67)。
- 本研究为回顾性研究且以利妥昔单抗治疗者为主,作者认为需持续评估所有可用数据以确定最佳风险/获益比。
核心结论
- 抗CD20治疗与未治疗的原发性进展型多发性硬化患者至首次确认残疾进展时间无统计学显著差异。
- 作者认为,尽管研究为回顾性且以利妥昔单抗治疗者为主,结果提示需持续评估所有可用数据以确定患者的最佳风险/获益比。
研究设计与样本
- 回顾性研究,使用法国多发性硬化登记数据库(Observatoire Français de la Sclérose En Plaques)数据。
- 纳入2016至2021年间接受或从未接受抗CD20治疗、基线扩展残疾状态量表评分≤6.5的原发性进展型多发性硬化患者。
- 共纳入1184例患者,其中治疗组426例、未治疗组758例;治疗组中295例接受利妥昔单抗、131例接受奥瑞利珠单抗。
- 采用逆概率治疗加权方法,时间至事件结局用加权比例Cox模型、MRI活动度用逻辑回归分析。
主要发现
- 至首次确认残疾进展时间:治疗组 vs 未治疗组 HR 1.13(95%CI 0.93-1.36,p=0.2113),无统计学显著差异。
- 至首次复发时间:治疗组复发患者较未治疗组少的趋势未达统计学显著(HR 0.83,95%CI 0.48-1.28,p=0.0809)。
- MRI活动度:两组间无显著差异。
- 治疗组中与确认残疾进展相关的风险因素为男性性别和多发性硬化病程。
- 严重感染发生率:治疗组每100人年6.67(95%CI 3.12-14.25) vs 未治疗组每100人年2.67(95%CI 0.80-8.86)。
关键数值与推荐
- 基线时抗CD20治疗组较未治疗组更年轻(中位51.9岁 vs 58.6岁,Cohen d=0.683)且疾病活动度更高(54.5% vs 27.8%,Cohen d=0.562)。
- 纳入时91.6%的患者为初治。
- 总体中位年龄56岁(Q1-Q3 49.3-63.8),女性占52.7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究为回顾性研究。
- 研究主要纳入接受利妥昔单抗治疗的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Although rituximab failed to demonstrate a significant effect on disability progression in primary progressive multiple sclerosis (PPMS), ocrelizumab succeeded. Our main objective was to analyze confirmed disability progression (CDP) in a cohort of patients with PPMS treated with anti-CD20 therapies compared with a weighted untreated control cohort. METHODS: This was a retrospective study using data from the French MS registry (Observatoire Français de la Sclérose En Plaques). We included patients with PPMS treated or never treated with anti-CD20 therapies from 2016 to 2021, with an Expanded Disability Status Scale score of ≤6.5 at baseline. The primary outcome was time to first CDP. The secondary outcomes were time to first relapse, MRI activity at 2 years, identification of risk factors associated with CDP, and serious infection incidence rates (IIRs). Each outcome was studied using an inverse probability of treatment weighting method. The outcomes were modeled using a weighted proportional Cox model for the time-to-event outcomes and by a logistic regression regarding the MRI activity. RESULTS: A total of 1,184 patients (426 treated and 758 untreated) fulfilled the inclusion criteria. Median age (Q1-Q3) was 56 years (49.3-63.8), and 52.7% were female. Among treated patients, 295 received rituximab, whereas 131 received ocrelizumab. At baseline, anti-CD20-treated patients were younger (median 51.9 vs 58.6 years, Cohen d = 0.683) and had more active disease (54.5 vs 27.8%, Cohen d = 0.562). 91.6% were drug-naive at inclusion. In time to first CDP analysis, no statistical significance was observed (hazard ratio [HR], 1.13; 95% CI 0.93-1.36, p = 0.2113). In time to first relapse analysis, a nonsignificant trend toward fewer patients relapsing in the treated group was observed (HR 0.83; 95% CI 0.48-1.28, p = 0.0809). For MRI activity, no significant difference was found between the 2 groups. Risk factors associated with CDP in the treated group were male sex and MS duration. IIR was 6.67 (95% CI 3.12-14.25) per 100 person-years in the treated group vs 2.67 (95% CI 0.80-8.86) in the untreated group. DISCUSSION: Time to first CDP was not different between anti-CD20 treated and untreated patients with PPMS. Although our study is retrospective and mainly included patients treated by rituximab, our results indicate that there should be a constant evaluation of all available data to ascertain the best risk/benefit ratio for patients with PPMS. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that anti-CD20 therapy of previously untreated patients with PPMS was not superior to no therapy in delaying time to first CDP.
引用
- Hay M, Rollot F, Casey R, et al. Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study. Neurology. 2024. PMID: 39321406. doi:10.1212/WNL.0000000000209886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。